Phase 1 N=94 A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
Advanced Cancer
Primary: Recommended Dose for Phase 2 Studies : Maximum Tolerated Dose (MTD) — 16 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
Cancer · Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE) — 0; 0; 0; 0 Participants
Phase 1 N=36 Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
Carcinoma of the Head and Neck
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) — 1 Participants
Phase 1 N=41 Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
Multiple Myeloma · Advanced Solid Tumors
Primary: Unbound Cmax: Unbound Maximum Observed Plasma Concentration for Ixazomib — 0.300; 0.478; 0.213 ng/mL
Phase 1 N=12 A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-536 — 652.6; 609.4 nanogram per milliliter (ng/mL)
Phase 1 N=6 Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Post-operative Nausea and Vomiting
Primary: Mass Balance — 96.4 percent excreted
Phase 1 N=77 A Study of LY3127760 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=80 Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Infections, Meningococcal
Primary: Number of Subjects With Any Solicited Local and Systemic Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 1 N=6 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score
Phase 1 N=24 Ibuprofen 4% (w/v) Pivotal Bioequivalence Study
Bioequivalence of the Test Formulation
Primary: Maximum Plasma Concentration (Cmax) of Ibuprofen — 38.503; 25.162; 33.843; 26.432 μg/ml
Phase 1 N=138 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 769.069; 771.680; 834.680; 810.054 µg·h/mL
Phase 1 N=36 A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants
Phase 1 N=12 To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Migraine
Primary: Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion — 1; 1; 8; 6 Participants
Phase 1 N=56 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
Healthy
Primary: Number of Participants With Shigellosis — 0; 2; 1; 4 Participants
Phase 1 N=32 Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance
Chronic Kidney Disease
Primary: Number of Participants With Clinically Significant Effects (Adverse Events) — 0; 0; 0; 0 Participants